AU2020299953B2 - A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator - Google Patents

A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator Download PDF

Info

Publication number
AU2020299953B2
AU2020299953B2 AU2020299953A AU2020299953A AU2020299953B2 AU 2020299953 B2 AU2020299953 B2 AU 2020299953B2 AU 2020299953 A AU2020299953 A AU 2020299953A AU 2020299953 A AU2020299953 A AU 2020299953A AU 2020299953 B2 AU2020299953 B2 AU 2020299953B2
Authority
AU
Australia
Prior art keywords
formula
compound
methyl
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020299953A
Other languages
English (en)
Other versions
AU2020299953A1 (en
Inventor
Ali Ates
David SKOLC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2020299953A1 publication Critical patent/AU2020299953A1/en
Application granted granted Critical
Publication of AU2020299953B2 publication Critical patent/AU2020299953B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2020299953A 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator Active AU2020299953B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183643.6 2019-07-01
EP19183643 2019-07-01
PCT/EP2020/068183 WO2021001288A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (2)

Publication Number Publication Date
AU2020299953A1 AU2020299953A1 (en) 2022-01-06
AU2020299953B2 true AU2020299953B2 (en) 2025-06-05

Family

ID=67137843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020299953A Active AU2020299953B2 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator

Country Status (23)

Country Link
US (1) US12643877B2 (enExample)
EP (1) EP3993794A1 (enExample)
JP (1) JP7510444B2 (enExample)
KR (1) KR20220029686A (enExample)
CN (2) CN117700395A (enExample)
AR (1) AR119318A1 (enExample)
AU (1) AU2020299953B2 (enExample)
BR (1) BR112021022378A2 (enExample)
CA (1) CA3139571A1 (enExample)
CL (1) CL2021002946A1 (enExample)
CO (1) CO2021018155A2 (enExample)
EC (1) ECSP21093559A (enExample)
IL (2) IL319939A (enExample)
MA (1) MA56440A (enExample)
MX (2) MX2021015873A (enExample)
MY (1) MY210361A (enExample)
PE (1) PE20221020A1 (enExample)
PH (1) PH12021552825A1 (enExample)
SA (1) SA521431279B1 (enExample)
SG (1) SG11202112537YA (enExample)
TW (1) TWI875776B (enExample)
WO (1) WO2021001288A1 (enExample)
ZA (1) ZA202109193B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
SI4263517T1 (sl) 2020-12-18 2025-01-31 UCB Biopharma SRL Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1
CN116685308A (zh) 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
ES3004257T3 (en) 2020-12-18 2025-03-12 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途
WO2026022198A1 (en) 2024-07-25 2026-01-29 UCB Biopharma SRL Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109336A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
WO2014193781A1 (en) * 2013-05-30 2014-12-04 Eli Lilly And Company 3,4-dihydroisoquinolin-2(1h)-yl compounds
WO2016055479A1 (en) * 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
WO2017178377A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109336A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
WO2014193781A1 (en) * 2013-05-30 2014-12-04 Eli Lilly And Company 3,4-dihydroisoquinolin-2(1h)-yl compounds
WO2016055479A1 (en) * 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
WO2017178377A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Also Published As

Publication number Publication date
SG11202112537YA (en) 2021-12-30
WO2021001288A9 (en) 2021-09-02
TWI875776B (zh) 2025-03-11
IL289314A (en) 2022-02-01
PH12021552825A1 (en) 2022-10-03
US12643877B2 (en) 2026-06-02
ZA202109193B (en) 2023-11-29
AU2020299953A1 (en) 2022-01-06
CN113993857A (zh) 2022-01-28
MX2021015873A (es) 2022-02-03
TW202537959A (zh) 2025-10-01
SA521431279B1 (ar) 2024-01-09
MX2024015493A (es) 2025-02-10
IL319939A (en) 2025-05-01
IL289314B2 (en) 2025-09-01
TW202115010A (zh) 2021-04-16
US20220259179A1 (en) 2022-08-18
CN117700395A (zh) 2024-03-15
MA56440A (fr) 2022-05-11
CL2021002946A1 (es) 2022-07-15
KR20220029686A (ko) 2022-03-08
CN113993857B (zh) 2024-01-02
IL289314B1 (en) 2025-05-01
JP7510444B2 (ja) 2024-07-03
ECSP21093559A (es) 2022-02-25
PE20221020A1 (es) 2022-06-16
CA3139571A1 (en) 2021-01-07
WO2021001288A1 (en) 2021-01-07
MY210361A (en) 2025-09-13
BR112021022378A2 (pt) 2022-03-08
AR119318A1 (es) 2021-12-09
JP2022539152A (ja) 2022-09-07
CO2021018155A2 (es) 2022-01-17
EP3993794A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
TWI875776B (zh) 作為ｄ１正向異位調節劑之經取代的四氫異喹啉衍生物及其用途
EP4263522B1 (en) Dihydroisoquinolinyl derivatives
AU2020299705B2 (en) A substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
US20180170935A1 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
EP4263517B1 (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
RU2824581C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
HK40058931A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40058931B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)